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Edited by Berend WieringaAbstract The neurodegenerative disorder X-linked adrenoleu-
kodystrophy (X-ALD) is caused by ABCD1 mutations and char-
acterized by very long-chain fatty acid (VLCFA) accumulation.
Cholesterol-lowering normalized VLCFA in ﬁbroblasts and plas-
ma of X-ALD patients. We show that in cultured cells, choles-
terol-loading induces ABCD1. In X-ALD mice, plasma
cholesterol is elevated and not further increasable by choles-
terol-feeding, whereas hepatic HMG-CoA reductase and Abcd2
are downregulated. Upon cholesterol modulation, brain VLCFA
increased in X-ALD mice, but decreased in controls. In murine
X-ALD ﬁbroblasts, cholesterol-lowering did not normalize
VLCFA. Thus, ALDP-deﬁciency and VLCFA are linked to cho-
lesterol but species diﬀerences complicate evaluating cholesterol-
lowering drugs in X-ALD mice.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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X-linked adrenoleukodystrophy (X-ALD; OMIM 300100),
the most frequent peroxisomal disorder, is a severe neurodegen-
erative disease for which currently no satisfying cure is avail-
able. The biochemical characteristicum of X-ALD is the
accumulation of very long-chain fatty acids (VLCFA) in body
ﬂuids and tissues, which should normally be degraded by perox-
isomal b-oxidation. It is still unclear how increased VLCFA are
connected to the pathophysiology of X-ALD, i.e., loss ofmyelin
and destruction of adrenocortical cells. The disease-associated
gene ATP-binding cassette (ABC) transporter subfamily D
member 1 (ABCD1, ALD) encodes a peroxisomal ABC-half
transporter, adrenoleukodystrophy protein (ALDP), with un-
known function [1]. Interestingly, ABCD1 expression was dem-
onstrated to be upregulated when primary humanmacrophagesAbbreviations: ABCD1, ATP-binding cassette transporter subfamily D
member 1; ALDP, adrenoleukodystrophy protein; VLCFA, very long-
chain fatty acids; X-ALD, X-linked adrenoleukodystrophy
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doi:10.1016/j.febslet.2005.09.014were loaded with acetylated low-density lipoprotein [2], thus
linking ALDP function to cholesterol metabolism.
Modulation of cellular cholesterol by either cholesterol
depletion [3] or treatment with the cholesterol-lowering drug
lovastatin [4] normalizes VLCFA accumulation in human X-
ALD ﬁbroblasts. Thus, a relationship between degradation
of VLCFA and cholesterol levels is evident. Lovastatin, which
reduces cellular cholesterol by inhibiting HMG-CoA reduc-
tase, the key enzyme in cholesterol biosynthesis, seemed prom-
ising for therapy of X-ALD because it decreased plasma
VLCFA in X-ALD patients [5]. However, it remains diﬃcult
to determine whether lowering of cholesterol reduces VLCFA
accumulation also in other tissues, in particular the brain, of
X-ALD patients.
Abcd1-deﬁcient mice also accumulate VLCFA in tissues [6–
8]. Thus, this animal model for X-ALD seemed to be useful for
assessing the eﬀects of lovastatin on VLCFA metabolism. Two
studies have addressed this issue, but in both studies statin
treatment did not normalize VLCFA in X-ALD mice [9,10].
However, it is generally accepted that in many respects, choles-
terol metabolism in the mouse is diﬀerent from other species,
particularly primates [11]. Accordingly, several reports demon-
strated that statins alone have no signiﬁcant eﬀect on either
plasma or liver cholesterol in rodents [12,13]. In contrast, when
statins were combined with bile acid sequestrants (colestipol),
maturation of the transcription factors controling hepatic cho-
lesterol synthesis, sterol regulatory element binding proteins
(SREBPs), was aﬀected, suggesting that such a combinatorial
treatment regime is required to modulate cholesterol metabo-
lism in mice [14].
Thus, the aim of the present work was: (a) to evaluate the
link between VLCFA accumulation, Aldp-deﬁciency and cho-
lesterol metabolism in X-ALD mice; and (b) to investigate
whether changing the cholesterol content in X-ALD mice by
either feeding high cholesterol or treatment with lovastatin/
colestipol aﬀects tissue VLCFA accumulation.2. Materials and methods
2.1. Mice and dietary treatment
Male 4–6-months-old wild-type and Abcd1-deﬁcient mice [6] back-
crossed to C57BL/6 for 10 generations, were kept at a temperature
of 22 C with equal periods of darkness and light. For high cholesterol
or lovastatin/colestipol treatment, mice were fed ad libitum either stan-
dard mouse chow (ssniﬀ) or standard chow enriched with 2% choles-
terol or supplemented with 0.1% lovastatin (VWR) and 2%
colestipol (Pharmacia), custommade by ssniﬀ. Groups consisting of
three animals each were treated for six weeks and sacriﬁced in the mid-
dle of the light phase.blished by Elsevier B.V. All rights reserved.
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Total plasma cholesterol was assessed by spectrophotometry using
the cholesterol oxidase method (CHOL cholesterol reagent, Roche)
according to the manufacturers instructions. Whole blood samples
were collected from sacriﬁced mice and centrifuged at 2000 rpm at
room temperature for 10 min. The supernatant was transferred to a
new tube and centrifugation repeated. Resulting plasma was stored
at 20 C until analysis.
2.3. Cell culture
THP-1 cells (TIB-202, ATCC), human primary skin ﬁbroblasts from
X-ALD and non-diseased persons (provided by Drs. E. Conzelmann,
University of Wu¨rzburg, Germany, and B. Molzer, Medical University
of Vienna, Austria, respectively) and murine primary embryonic X-
ALD and wild-type ﬁbroblasts (provided by Dr. H. Werner, Max
Plank Institute of Experimental Medicine, Germany) were cultivated
in DMEM with 10% FCS. For cholesterol depletion, standard FCS
was substituted with 10% lipoprotein-deﬁcient FCS (Sigma); for
cholesterol loading, 10 lg/ml cholesterol (Sigma) and 1 lg/ml 25-
hydroxycholesterol were added to the lipid-deﬁcient FCS. 22-(R)-
hydroxycholesterol (Sigma) was used at 10 lM for 24 h.
2.4. RNA isolation and Northern blot
Total RNA was isolated from murine liver using TriPure Isolation
Reagent (Roche) and a Polytron PT3100 homogenizer (Kinematica).
For cultured cells, RNeasy Mini kit (Quiagen) was used. Membranes
containing 10 lg of total RNA per lane were hybridized with a
[a-32P]dCTP-labeled cDNA probe for acidic ribosomal phosphopro-
tein P0 (36B4, nucleotides 9-969, GenBank Accession No.
BC011106) or HMG-CoA reductase (nucleotides 338–734 , GenBank
Accession No. NM_008255).
2.5. Quantitative real time RT-PCR (QRT-PCR)
Per assay, 12 ng cDNA (generated by GeneAmp RNA PCRKit, Ap-
plied Biosystems) were analyzed using the iCycler iQ real-time PCR
detection system (Bio-Rad). For quantiﬁcation of human ABCD1
expression, the primers nt1815 5 0-GAGAACATCCCCATCGTC-3 0
(forward); nt1983 5 0-TGTAGAGCACACCACCGTA-3 0 (reverse);
and nt1925 5 0-ACATCAGGGTGGAGGAAGGCAT-3 0 (TaqMan
probe) were used. For murine Abcd2, primers were: nt1959, 5 0-CAC-
AGCGTGCACCTCTAC-3 0 (forward); primer nt2032, 5 0-AGGA-
CATCTTTCCAGTCCA-3 0 (reverse); nt1986, 5 0-HEX-CAAAGAGA-
AGGAGGATGGGATGC-TAMRA-3 0 (TaqMan probe). As a con-
trol, hydroxy-phosphoribosyl transferase (HPRT) mRNA levels were
quantiﬁed: human: nt504 5 0-GCAAAACAATGCAGACTT-30 (for-
ward), nt613 5 0-TGGCTTATATCCAACACTTC-3 0 (reverse), nt567
5 0-CAAGCTTGCTGGTGAAAAGGA-3 0 (TaqMan probe); murine:
nt430, 5 0-AAAGTTATTGGTGGAGATGA-3 0 (forward), nt518, 5 0-
TGCATTGTTTTACCAGTGTC-3 0 (reverse), nt454, 5 0-FAMTCAA-
CTTTAACTGGAAAGAATGTCTTGA-DABCYL-30 (TaqMan
probe). Standard curves for quantiﬁcation were generated by serial dilu-
tion of plasmids containing ABCD1, Abcd2 or HPRT (provided by Dr.
D.W. Melton, University of Edinburgh, UK) cDNA. The thermocycler
was programmed: 95 C for 10 min followed by 50 cycles at 95 C for
20 s and 58 C for 50 s.
2.6. Analysis of VLCFA concentration in ﬁbroblasts and tissues
For measurement of VLCFA accumulation, ﬂash-frozen brain tissue
or ﬁbroblasts harvested from a conﬂuent 75 cm2 culture ﬂask were
used. After adding C23:0 as an internal standard, total lipids were ex-
tracted, converted to methyl esters, puriﬁed by thin-layer chromatog-
raphy and subjected to capillary gas-chromatographic analyses as
described previously [6].Fig. 1. Cholesterol and oxysterols regulate ABCD1 expression. Human
THP-1 cells were either (A) cultured in medium containing standard
FCS, lipid-deﬁcient FCS or lipid-deﬁcient FCS with added sterols or
(B) treated with 10 lM 22-(R)-hydroxycholesterol for 24 h. The
number of ABCD1 mRNA copies was evaluated by QRT-PCR and
normalized to HPRT mRNA copies. Data are shown as means ± SD
with the number of analyzed samples in parantheses. Statistically
signiﬁcant diﬀerences by Students t-test are indicated by asterisks
(P < 0.05).3. Results
Statins inhibit cholesterol biosynthesis, thereby normalizing
VLCFA accumulation caused by ABCD1-deﬁciency in X-
ALD ﬁbroblasts [4]. Thus, we determined how cellular choles-
terol aﬀects ABCD1 expression. Using QRT-PCR, ABCD1
mRNA levels were quantiﬁed in human THP-1 monocytescultured either under standard conditions, in lipid-deﬁcient
medium or in lipid-deﬁcient medium with added sterols. Lack
of lipids including cholesterol resulted in signiﬁcantly reduced
ABCD1 expression, whereas adding back cholesterol to lipid-
depleted cells avoided the observed reduction (Fig. 1A). This
conﬁrmes previous results showing upregulation of ABCD1
in human primary macrophages during cholesterol inﬂux med-
iated by acetylated low-density lipoprotein [2]. Intracellularly,
excessive cholesterol is converted to oxysterols. Thus, we next
determined whether also oxysterols regulate ABCD1 expres-
sion (Fig. 1B). Treatment of THP-1 cells with 22-(R)-hydroxy-
cholesterol for 24 h resulted in approximately 2-fold increased
ABCD1 mRNA levels, indicating that ABCD1 expression is
linked to degradation or export of cholesterol (Fig. 1B).
To elucidate whether in vivo, Aldp-deﬁciency is connected to
abnormalities in cholesterol metabolism, plasma total choles-
terol was investigated in X-ALD mice consistently backcrossed
to the C57BL/6 background for 10 generations. In X-ALD
mice, signiﬁcantly higher total plasma cholesterol levels (28%)
were observed compared with age-matched wild-type litter-
mates (Fig. 2A). When control mice were dietary treated with
cholesterol for six weeks, plasma cholesterol increased by
27%, whereas virtually no change was observed in X-ALDmice
(Fig. 2B). Thus, Aldp-deﬁciency results in abnormally high
plasma total cholesterol, comparable to levels observed in cho-
lesterol-fed wild-type controls. In contrast, feeding a diet sup-
plemented with the cholesterol-lowering drugs lovastatin and
colestipol did not signiﬁcantly change plasma cholesterol levels
in neither wild-type nor X-ALD mice (data not shown).
To further deﬁne whether the cholesterol-load of X-ALD
mice is due to increased hepatic de novo synthesis, expression
of the key enzyme HMG-CoA reductase was investigated by
northern blotting. Surprisingly, HMG-CoA reductase was
downregulated in the liver of X-ALD mice compared with
wild-type controls (Fig. 3A), indicating that hepatic cholesterol
biosynthesis is not increased. We have previously shown that
Abcd2, which encodes a protein functionally related to Aldp
Fig. 2. Plasma total cholesterol is induced in X-ALD mice and cannot be further increased by high cholesterol feeding. Total plasma cholesterol was
determined in X-ALD mice and wild-type littermates after (A) feeding standard mouse chow or (B) dietary treatment with high cholesterol for six
weeks. Results are shown as means ± SD with the number of treated animals in parantheses. Statistically signiﬁcant diﬀerences by Students t-test are
indicated by asterisks (P < 0.05).
Fig. 3. X-ALD mice demonstrate altered hepatic expression of choles-
terol regulated genes. Hepatic total RNA from X-ALD mice and wild-
type controls was analyzed for (A) HMG-CoA reductase expression
using northern blot technique and (B) Abcd2 mRNA levels using
QRT-PCR with data shown as means ± SD and the number of treated
animals in parantheses. Statistically signiﬁcant diﬀerences by Students
t-test are indicated by asterisks (P < 0.05).
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Thus, we also looked whether increased cholesterol levels in
X-ALD mice inﬂuence hepatic Abcd2 expression. Accordingly,Fig. 4. Eﬀect of 6-weeks cholesterol feeding or lovastatin/colestipol treatment o
feeding a standard diet, a standard diet supplemented with cholesterol
chromatography. Data represent the means ± SD of three mice and statistic
(P < 0.05).QRT-PCR analysis revealed that Abcd2 is downregulated in
the liver of X-ALD mice (Fig. 3B).
We next asked whether lowering or increasing cholesterol
in X-ALD mice aﬀects VLCFA metabolism. Thus, mice were
dietary treated with either lovastatin and colestipol or high
cholesterol for six weeks and brain VLCFA accumulation
was assessed. As expected, VLCFA accumulate in brain
tissue of untreated X-ALD mice to levels comparable with
X-ALD patients (Fig. 4A). After treatment with lovastatin/
colestipol, C26:0 levels increased intriguingly by 11% in
X-ALD mice (Fig. 4B), conﬁrming a previous report showing
increased brain VLCFA after simvastatin treatment [10]. On
the contrary, wild-type controls demonstrated a signiﬁcant
decrease in brain C26:0 content (45%; Fig. 4C). When
X-ALD mice were fed a high cholesterol diet, the brain
C26:0 level increased by 16% (Fig. 4B), whereas cholesterol
treatment of wild-type mice produced a decrease of 58%
(Fig. 4C).
In contrast to X-ALD mice, cholesterol-lowering is associ-
ated with decreased VLCFA in ﬁbroblasts and plasma of X-
ALD patients [4,5]. Thus, we investigated whether the general
mechanism underlying the connection between cholesteroln brain VLCFA accumulation in X-ALD or wild-type control mice. After
or lovastatin/colestipol, brain C26:0 levels were determined by gas
ally signiﬁcant diﬀerences by Students t-test are indicated by asterisks
Fig. 5. Cholesterol-lowering does not normalize VLCFA levels in murine
X-ALD ﬁbroblasts. Human or murine X-ALD and healthy control
ﬁbroblasts were cultured in medium containing standard FCS or lipid-
deﬁcient FCS for 10 days. The C26:0 levels of two pooled conﬂuent
T75-cell culture ﬂasks were determined by gas chromatography.
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and mouse. To address this, we examined whether cholesterol
depletion aﬀects VLCFA accumulation in primary murine X-
ALD ﬁbroblasts. Cholesterol-depletion did reduce C26:0 accu-
mulation to a lesser extent in murine than in human primary
X-ALD ﬁbroblasts (Fig. 5), indicating signiﬁcant species diﬀer-
ences in cause and eﬀect relationship between VLCFA accu-
mulation and cellular cholesterol levels.4. Discussion
The cholesterol-lowering drug lovastatin has been proposed
as a possible therapeutic intervention in X-ALD and a correla-
tion between plasma VLCFA and cholesterol levels has been
observed in X-ALD patients and cultured ﬁbroblasts [4,5].
This predicted a link between cholesterol metabolism and
ALDP function.
In human monocytes, treatment with either cholesterol or
oxysterols resulted in increased ABCD1 mRNA levels, indicat-
ing that ALDP function is somehow connected to the choles-
terol status of the cell. Thus, regulation of ABCD1 shows
similarities to other genes encoding ABC-transporters involved
in cholesterol degradation and export, e.g., ABCA1, ABCG5
and ABCG8 [17,18]. Cholesterol aﬀects gene expression by
activating the nuclear liver X receptor (LXR). Whereas
ABCA1, ABCG5 and ABCG8 contain elements for LXR-bind-
ing and activation, inspection of the ABCD1 promoter did not
reveal such a sequence. In addition, LXR co-transfection did
not induce ABCD1 promoter reporter-constructs (data not
shown). Thus, the mechanism by which cholesterol aﬀects
ABCD1 expression is currently unclear.
The link between ALDP and cholesterol metabolism is
further strengthened by the ﬁnding that X-ALD mice on
the pure C57BL/6 background demonstrate increased plasma
total cholesterol, comparable with the level observed in cho-
lesterol-fed wild-type controls. This raised the question
whether the cholesterol-load of X-ALD mice is due to in-
creased hepatic de novo synthesis and reﬂected by dysregula-
tion of cholesterogenic enzymes. Unexpectedly, hepatic
expression of HMG-CoA reductase encoding the key enzyme
of cholesterol biosynthesis, was reduced in X-ALD mice.
This indicates that not synthesis but either uptake ordegradation and export of cholesterol is disturbed. In
addition to HMG-CoA reductase, also hepatic expression of
the Abcd1-related Abcd2 gene was decreased in X-ALD
mice, supporting our recent observation that high cholesterol
feeding results in downregulation of hepatic Abcd2 (manu-
script submitted) and further implicates abnormalities in
X-ALD cholesterol metabolism.
In contrast to inbred mice, plasma cholesterol in man is
highly variable due to diﬀerent factors including life-style
and genetic predisposition. Thus, a large-scale study involving
a high number of patients would be needed to deﬁne whether
also human X-ALD is connected with abnormalities in
cholesterol metabolism, reﬂected by increased total plasma
cholesterol.
A ﬁnal intriguing observation is that both feeding high cho-
lesterol or cholesterol lowering by lovastatin/colestipol treat-
ment increased brain VLCFA in X-ALD mice, whereas a
decrease was observed in wild-type controls. Statins have been
previously demonstrated to cross the blood–brain barrier and
alter brain gene expression [19] as well as increase C26:0 con-
tent in various tissues of X-ALD mice, including brain, adre-
nals and liver [10]. In contrast, the ﬁnding that also
cholesterol feeding inﬂuences brain VLCFA is surprising, but
supported by published reports demonstrating that dietary
cholesterol alters brain metabolism, including changes in sterol
recycling and gene expression [20,21]. In tissues aﬀected by X-
ALD, VLCFA mainly accumulate in the form of cholesterol
esters. Thus, modiﬁed transcription of genes induced by feed-
ing high cholesterol might alter VLCFA metabolism and pos-
sibly cholesterol availability in the brain of X-ALD mice.
In murine X-ALD ﬁbroblasts, cholesterol-lowering did not
normalize VLCFA accumulation to healthy control levels.
Thus, the eﬀects of cholesterol-depletion on abnormal VLCFA
metabolism appear to be less in murine than in human X-ALD
ﬁbroblasts.
In conclusion, the use of our X-ALD mouse model on the
pure C57BL/6 background enabled us to disclose a clear link
between Aldp-deﬁciency and cholesterol abnormalities. In view
of these data, the observation of increased VLCFA accumula-
tion after high dietary intake of cholesterol could be of concern
for therapeutic interventions in X-ALD. However, species dif-
ferences complicate the eﬃcacy of cholesterol modulation on
X-ALD pathology, thus, more studies involving X-ALD
patients are necessary to evaluate whether cholesterol-lowering
could be a therapeutic approach for X-ALD.
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